PPT-Influenza

Peggy Beeley MD Best Practice 11514 Outline Current Outbreak Brief review of Influenza structure amp subtypes Transmission and Prevention Available Testing Treatment Prophylaxis Signs amp Symptoms. 2009 - 2010. Armed Forces Health Surveillance Center (AFHSC). United States Air Force School of Aerospace Medicine (USAFSAM). Naval Health Research Center (NHRC). DoD Global Influenza Network Partners (GEIS Operations). 1. October 2013. Max Planck Institute Magdeburg. Options for continuous production of . cell culture-derived viral vaccines. MAX-PLANCK-INSTITUT. DYNAMIK KOMPLEXER. TECHNISCHER SYSTEME. MAGDEBURG. Frensing. Page 1 of 1. * required for saving. ^ conditionally required. *Facility ID:. DO NOT VACCINATE (Check one). (*Imprint patient information or place patient label here). Patient is less than 6 months old.. 2014-2015 . Season:  . What . you need to know. September 11, 2014. Cindy Schulte, RN, BSN. Kathy Sen, RN, BSN. Vaccine Preventable Disease Surveillance. Bureau of Immunization. New York State Department of Health (NYSDOH). Industry Perspective for 2014-15 NH Vaccine Supply. The FDA CBER requested this annual summary of information from influenza vaccine manufacturers supplying the U.S., for purposes of a general presentation to the VRBPAC. This summary has been prepared  from a variety of public sources, and was reviewed by AstraZeneca, bioCSL, GSK, Novartis, Protein Sciences, and Sanofi Pasteur.. Les Sims. Asia Pacific Veterinary Information Services. apvis@bigpond.net.au. Background. Animal influenza is not eradicable. Possible to eliminate certain strains of virus. Equine influenza in Australia. Bailey Inglis. You all know the symptoms of the flu…. Influenza is transmitted through personal contact. INFLUENZA IS A RNA VIRUS. with an 8 piece RNA genome!!!. It is enclosed by a lipid bilayer . Rakhee Palekar, MD, MPH. PAHO/WHO. Background. Influenza A.  subtype H1, H3, . etc. Influenza B distinct lineages emerged in 1970’s B-Yamagata & B-Victoria co-circulated since 2001. Julia . Fitzner. Based on slides from . Kaat. . Vandemaele. Global Influenza . Programme. WHO Geneva. IHR Review Committee. . WHO . should develop and apply measures that can be used to assess severity of every influenza pandemic.. Dr. Yogiraj Ray. Assistant . Professor. Dr. . Parikshit. . Mullick. Junior Resident. Department of Tropical Medicine. School of Tropical Medicine. Case. A person presented with:. fever (temp > 100) for last 3 days. Two funded influenza vaccines. Key campaign messages. 2018 promotional campaign . Eligibility. Influenza - the disease. 2018 vaccines and strains. Precautions and contraindications. Influenza and healthcare workers. Orthomyxoviridae family of viruses. RNA enveloped viruses that make up three genera. Influenzavirus A. Influenzavirus B. Influenzavirus C. The type A viruses are the most virulent among the three, genetically diverse and infecting human, birds and animals. The influenza virus group consists of three enveloped RNA members of the family Orthomyxoviridae:. influenza A, B, and C. . Influenza A . viruses are further classified into hemagglutinin (H) and neuraminidase. RNA virus. of the family . Orthomyxoviridae. that is responsible for the infectious disease . influenza. (or most commonly referred to as flu) in birds, various mammals (such as pigs) and humans. Typically, influenza is characterized by fever, sore throat, chills and other non-specific symptoms, it is a much more severe disease. It is spread around the world in seasonal epidemics and according to World Health Organization, these annual epidemics result in about three to five million cases of severe illness, and about 250 000 to 500 000 deaths..